Peer-reviewed veterinary case report
Outcome of high-grade soft tissue sarcoma in dogs
By Selting, Kim A et al.·Published in Journal of the American Veterinary Medical Association·2005·Department of Veterinary Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996-2004).
- Species:
- dog
Plain-English summary
A group of 39 dogs with high-grade soft tissue sarcomas (a type of cancer) was studied to see if adding doxorubicin chemotherapy after surgery would improve their outcomes. The dogs were treated either with surgery alone or with surgery followed by doxorubicin. Unfortunately, the results showed that the chemotherapy did not provide any additional benefits in terms of survival or disease-free intervals compared to surgery alone. On average, the dogs lived about 856 days after treatment, regardless of whether they received chemotherapy.
People also search for: dog soft tissue sarcoma treatment · doxorubicin for dogs cancer · dog cancer survival rates
Abstract
OBJECTIVE: To examine the effect of adjuvant doxorubicin chemotherapy on outcome in dogs with high-grade (grade 3) soft tissue sarcomas (HGSTSs). DESIGN: Retrospective case series. ANIMALS: 39 dogs. PROCEDURES: Medical records of dogs with HGSTSs were reviewed. Dogs treated with surgery alone or receiving single-agent doxorubicin chemotherapy postoperatively were included in the study. Owners and referring veterinarians were contacted for follow-up information. Slides from histologic sections were reviewed to confirm the diagnosis of HGSTSs. Cases in which follow-up examination was not performed and radiation therapy or chemotherapy other than doxorubicin was administered were excluded. RESULTS: 39 dogs met inclusion criteria. Twenty-one dogs received adjuvant doxorubicin. Tumor-, patient-, and treatment-related variables were not significantly associated with measured outcomes including local, metastatic, and overall disease-free intervals as well as survival time. Overall median disease-free interval was 724 days with a median survival time of 856 days for all dogs. CONCLUSIONS AND CLINICAL RELEVANCE: Adjuvant doxorubicin-based chemotherapy did not benefit this population of dogs with HGSTSs. Outcome for visceral HGSTSs was similar to that of nonvisceral HGSTSs in these cases.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16279389/